Abstract
There is confusion in the literature on the measurement of the drug activity onset time (AOT) for both clinical and non-clinical studies of antidepressant and antimanic drugs. The questions asked are: How often and at which time points should drug effects be measured? At what level of a drug effect should AOT be determined? Is the placebo (control) effect important for consideration of drug AOT? This paper reviews approaches taken to answer these questions and to assess drug therapeutic AOT. The first part of the paper is devoted to a review of methods used in clinical trials with depression as an indication. The second part is focused on approaches taken in animal models of depression and how they could help in assessing drug AOT. Finally, a summary of pharmacological values on which the AOT depends is presented and a new statistical approach to data analysis method proposed. The allied experimental design for pre-clinical and clinical studies may help to characterize and differentiate AOT for available and new generation of antidepressants and antimanic drugs.
Original language | English |
---|---|
Pages (from-to) | 904-919 |
Number of pages | 16 |
Journal | Neuroscience and Biobehavioral Reviews |
Volume | 31 |
Issue number | 6 |
DOIs | |
State | Published - 2007 |
Externally published | Yes |
Keywords
- Activity onset time
- Animal models
- Antidepressants
- Antimanic drugs
- Clinical trials
- Depression
- Levenberg-Marquardt algorithm
- Mania
- Non-linear regression analysis
- Reduction of dominant behavior model
- Reduction of submissive behavior model